Curium Pharma

curiumpharma.com · Chesterfield, United States of America

Curium Pharma is a global nuclear medicine company that develops, manufactures, and supplies diagnostic and therapeutic radiopharmaceuticals used primarily in oncology, cardiology, neurology, and other specialty indications. It serves hospitals, imaging centers, and healthcare providers through a network of production facilities and radiopharmacies, generating revenue from the sale and distribution of its nuclear medicine products and related services.

Revenue
$900.0M
Employees
2,000
Founded
2017
Headquarters
Chesterfield, United States of America

What 10 Arbolus experts think of Curium Pharma

The NPS distribution is heavily positive, with 78% of experts providing an NPS score of 8 to 10. Renewal intent is strong, as 88% express intent to renew, and only a small minority report uncertainty. Implementation stage data shows a majority (67%) are long-term users, with the balance in the pilot stage. Positive NPS and high renewal intent cluster among long-term, high-spend users, especially in clinical and pharma environments. Negative or neutral sentiment is isolated to pilot-phase users with uncertain renewal intentions.Overall Customer Sentiment: Positive

Who reviewed Curium Pharma

Total customers 10 8 current · 2 former
Reviews growth +4 in six months
Seniority of respondents
  • C-Suite 56% (6)
  • Director 44% (4)
Other Partner Not specified NPS 10
Other Generalist C-Suite NPS 8 Will renew
Legal Leader Director NPS 5 Undecided

Employer names and spend open once the report publishes.

Tell us when the Curium Pharma report publishes.

We'll email you once the full customer report is ready, with employer names, spend and every written answer. No account needed.

Notify me

Sentiment

20 Net Promoter Score, from 10 scored reviews
  • Promoters 4
  • Passives 4
  • Detractors 2

Cumulative NPS by month

-1 over 5 months
  • Jun 9
  • Jan 8
  • Mar 8
  • Jun 8
  • Jul 8

Net Promoter Score across 2 reviews, accumulated up to each month. Category median 28 across 2 companies.

Written answers and themes publish with the full report.

Renewal intent

Plan to renew 67%
  • Will renew 6
  • Undecided 3
  • Not renewing 0

Plan to renew, by seniority

  • C-Suite 60% 5 answers
  • Director 75% 4 answers
  • 8.5/10 Average score from customers who will renew
  • 6.3/10 Average score from undecided customers

Top alternatives

Most weighed by Curium Pharma customers

For people who use Curium Pharma

Do you use Curium Pharma at work?

Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.

  • 10 customers of Curium Pharma have already contributed
Share your experience

Takes a few minutes. Your identity stays anonymous.